Immunoproteasome inhibitors
US11225493B2 · kind B2 · utility
3Cited by
0References
32Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 14, 2018 |
| Grant date | Jan 18, 2022 |
| Priority date | — |
| Expiry date | Nov 14, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07F5/025
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Provided herein are compounds, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.